Formulary
Salbutamol (Albuterol): Uses, Dosing, Side Effects and Indian Brand Names
Salbutamol is the prototype short-acting beta-2 agonist (SABA) and the first-line reliever for acute bronchospasm in asthma and COPD. It provides rapid bronchodilation within 5 minutes via inhaled route and is the most important rescue medication in respiratory medicine.
MedNext Academy | 5 min read
Clinically reviewed by Awaiting clinical review
Salbutamol (Albuterol): Uses, Dosing, Side Effects and Indian Brand Names
Salbutamol is the prototype short-acting beta-2 agonist (SABA) and the first-line reliever for acute bronchospasm in asthma and COPD. It provides rapid bronchodilation within 5 minutes via inhaled route and is the most important rescue medication in respiratory medicine.
NEET PG High-Yield: Salbutamol is a SABA -- the rescue inhaler for acute asthma. Non-selective beta-blockers (propranolol) are CONTRAINDICATED in asthma -- a life-threatening interaction. Overuse indicates poorly controlled asthma. Salbutamol causes tremor (skeletal muscle beta-2), tachycardia, and HYPOKALAEMIA (drives K+ intracellularly). For exercise-induced asthma, give 2 puffs 15-20 min before exercise.
Clinical overview
Salbutamol is the most important bronchodilator in clinical medicine and is the prototype short-acting beta-2 agonist (SABA). It is the first-line reliever medication for acute bronchospasm in asthma, COPD exacerbations, and exercise-induced bronchoconstriction. Its rapid onset of action (within 5 minutes by inhalation) and short duration (4-6 hours) make it ideal as a rescue inhaler. According to GINA (Global Initiative for Asthma) guidelines, salbutamol should be used on an as-needed basis for symptom relief; overuse (>2 canisters per month or >12 puffs per day) indicates poorly controlled asthma and the need for step-up of controller therapy (inhaled corticosteroids). In India, salbutamol is one of the most commonly prescribed respiratory medications, available in metered-dose inhalers (MDI), nebuliser solutions, oral tablets, and syrups. The inhaled route is strongly preferred over oral formulations because inhaled salbutamol delivers drug directly to the airways with minimal systemic absorption, while oral salbutamol causes more systemic side effects (tremor, tachycardia, hypokalaemia) with less bronchodilation. Salbutamol is also used in obstetric practice as a tocolytic to delay preterm labour (by relaxing uterine smooth muscle via beta-2 receptors), though its use for this indication has declined in favour of nifedipine and atosiban due to maternal cardiovascular side effects.
Pharmacological class
Salbutamol (Albuterol) belongs to the Short-acting beta-2 adrenergic agonist (SABA; bronchodilator) class. Salbutamol selectively stimulates beta-2 adrenergic receptors on airway smooth muscle cells. Receptor activation stimulates adenylyl cyclase via Gs protein, increasing intracellular cAMP, which activates protein kinase A (PKA). PKA phosphorylates multiple targets leading to smooth muscle relaxation: inhibition of myosin light chain kinase, opening of large-conductance calcium-activated potassium channels (hyperpolarisation), and reduction of intracellular calcium. The net effect is bronchodilation within 5 minutes of inhalation.
Indian brand names and formulations
Available as: Asthalin (Cipla), Ventolin (GlaxoSmithKline), Derihaler (Cipla), Salbair (Lupin).
Metered-dose inhaler (MDI, 100 mcg/puff, 200 doses), Dry powder inhaler (Rotacaps 200 mcg), Nebuliser solution (2.5 mg/2.5 mL respules, 5 mg/2.5 mL), Tablets (2 mg, 4 mg), Syrup (2 mg/5 mL), Injection (0.5 mg/mL for IV/SC -- hospital use)
Regulatory status
Salbutamol (Albuterol) is classified under Schedule H in India under the Drugs and Cosmetics Act, 1940. Schedule H prescription drug. Metered-dose inhalers (MDIs) and nebuliser solutions are available. Oral formulations (tablets, syrups) are also Schedule H but are discouraged due to inferior efficacy-to-side-effect ratio.
Indications
- Acute bronchospasm in asthma (rescue/reliever therapy)
- COPD exacerbations (acute bronchodilation)
- Exercise-induced bronchoconstriction (prophylaxis -- 2 puffs 15-20 min before exercise)
- Acute severe asthma and status asthmaticus (nebulised, high-dose)
- Bronchospasm during anaesthesia
- Tocolysis in preterm labour (IV -- declining use)
- Hyperkalaemia (nebulised -- drives K+ intracellularly, same mechanism as in beta-2-mediated glycogenolysis)
Dosing
MDI (acute relief): 100-200 mcg (1-2 puffs) as needed, up to 4-6 times daily. Use with a spacer for optimal delivery. Nebulised (acute severe asthma): 2.5-5 mg every 20 minutes for 3 doses, then every 1-4 hours. Oral: 2-4 mg TDS-QDS (inferior to inhaled; avoid if possible). IV (status asthmaticus): 5 mcg/min infusion, titrate. Tocolysis (IV): 10 mcg/min, increase every 10 min. Exercise prophylaxis: 2 puffs 15-20 minutes before exercise.
Contraindications
- Known hypersensitivity to salbutamol
- Tachyarrhythmias (beta-2 stimulation increases heart rate)
- Hypertrophic obstructive cardiomyopathy (HOCM)
- Unstable angina (relative -- use with caution)
Adverse effects
- Tremor (most common, due to beta-2 receptor stimulation in skeletal muscle)
- Tachycardia and palpitations (beta-1 cross-reactivity at high doses)
- Hypokalaemia (beta-2 stimulation drives K+ intracellularly -- important in acute asthma with repeated dosing)
- Headache
- Muscle cramps
- Paradoxical bronchospasm (rare, due to propellants in MDI)
- Lactic acidosis (rare, with high-dose IV or nebulised therapy in severe asthma)
- Hyperglycaemia (glycogenolysis via beta-2 receptors)
Drug interactions
- Beta-blockers (propranolol) -- antagonise bronchodilator effect; AVOID non-selective beta-blockers in asthma (life-threatening bronchospasm)
- Theophylline -- additive bronchodilation but also additive tachycardia and hypokalaemia
- Corticosteroids and diuretics -- additive hypokalaemia
- Digoxin -- hypokalaemia from salbutamol increases digoxin toxicity risk
- MAO inhibitors and TCAs -- may potentiate cardiovascular effects
Pregnancy and lactation
Category C. Widely used in pregnancy for asthma (uncontrolled asthma is far more dangerous to the fetus than salbutamol). GINA guidelines recommend that pregnant women should not discontinue asthma medications. Also used as a tocolytic for preterm labour (IV), though maternal side effects (pulmonary oedema, tachycardia) limit this use. No established teratogenicity.
Exam-style clinical scenario
A 12-year-old boy with known asthma presents with acute severe breathlessness, widespread wheeze, and SpO2 88% on room air. He has used his salbutamol inhaler 6 times in the past 2 hours with minimal relief. What is the emergency management? Answer: This is acute severe asthma. Immediate management: (1) High-flow oxygen to maintain SpO2 94-98%, (2) Continuous nebulised salbutamol 5 mg every 20 minutes for 3 doses (driven by oxygen, not air), (3) Add ipratropium bromide 0.5 mg to the first 3 nebulisations, (4) IV/oral corticosteroids (prednisolone 1-2 mg/kg or hydrocortisone 4 mg/kg IV), (5) If no improvement: IV magnesium sulphate 40 mg/kg over 20 minutes, consider IV salbutamol infusion. Monitor for hypokalaemia from repeated salbutamol doses.
Cost in India
INR 100-200 per MDI (200 doses of 100 mcg); Nebuliser solution: INR 10-20 per respule (2.5 mg/2.5 mL); Tablets: INR 15-30 per strip
Clinical governance
Author: MedNext Editorial Team. Clinical reviewer: Awaiting clinical review. Jurisdiction: India (Drugs and Cosmetics Act, 1940). Sources: CIMS India, Indian Pharmacopoeia. Publication state: Awaiting clinical review. Correction: Report errors at support@mednext.academy.
Frequently Asked Questions
Why are non-selective beta-blockers contraindicated in asthma?
Non-selective beta-blockers (propranolol, carvedilol, labetalol) block beta-2 receptors on bronchial smooth muscle, preventing the bronchodilatory effect of circulating adrenaline and administered salbutamol. This can precipitate life-threatening bronchospasm in asthmatic patients. Even beta-1 selective blockers (atenolol, metoprolol, bisoprolol) lose selectivity at higher doses and should be used with caution. If a beta-blocker is needed in an asthmatic patient, use a cardioselective agent at the lowest effective dose.
Why is the inhaled route preferred over oral salbutamol?
Inhaled salbutamol delivers drug directly to the bronchial smooth muscle with minimal systemic absorption (only 10-20% of inhaled dose reaches the systemic circulation). This provides rapid onset (5 minutes vs 30 minutes oral), greater local effect with smaller doses (100-200 mcg inhaled vs 2-4 mg oral), and fewer systemic side effects (less tremor, tachycardia, hypokalaemia). Oral salbutamol is systemically absorbed from the GI tract, causing more side effects with less bronchial deposition.
How does salbutamol cause hypokalaemia?
Beta-2 receptor stimulation activates Na+/K+ ATPase in skeletal muscle cells via the cAMP-PKA pathway, driving potassium from the extracellular to the intracellular compartment. This is the same mechanism exploited when nebulised salbutamol is used to treat hyperkalaemia in emergency settings. In acute severe asthma with repeated high-dose nebulisations, clinically significant hypokalaemia can develop, potentially causing cardiac arrhythmias -- hence serum potassium monitoring is essential.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
Test yourself on Salbutamol (Albuterol)
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary